Mitsubishi UFJ Asset Management Co. Ltd. Buys New Stake in Taysha Gene Therapies, Inc. $TSHA

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 80,571 shares of the company's stock, valued at approximately $186,000.

• Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Other institutional investors and hedge funds also recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Taysha Gene Therapies during the 1st quarter valued at about $117,000. XTX Topco Ltd purchased a new position in Taysha Gene Therapies in the 1st quarter worth approximately $282,000. Jefferies Financial Group Inc. acquired a new stake in Taysha Gene Therapies in the first quarter valued at approximately $341,000. BIT Capital GmbH purchased a new stake in shares of Taysha Gene Therapies during the first quarter valued at approximately $163,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Taysha Gene Therapies by 15.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 547,128 shares of the company's stock worth $761,000 after buying an additional 72,871 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock.

Analyst Ratings Changes

TSHA has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research report on Friday, October 17th. JMP Securities set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Raymond James Financial assumed coverage on Taysha Gene Therapies in a research report on Tuesday, October 21st. They issued a "strong-buy" rating and a $13.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $10.30.

• 3 Small-Cap Stocks For Your Fall Shopping List

Read Our Latest Report on TSHA

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.78% of the company's stock.

Taysha Gene Therapies Stock Up 3.0%

Shares of Taysha Gene Therapies stock opened at $4.13 on Friday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.52 and a beta of 1.00. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $5.51. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The business's 50 day simple moving average is $4.10 and its 200-day simple moving average is $3.15.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More

• Five stocks we like better than Taysha Gene Therapies
• Market Cap Calculator: How to Calculate Market Cap
• Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
• Low PE Growth Stocks: Unlocking Investment Opportunities
• 3 Under-the-Radar AI Stocks to Buy on the Dip
• 3 Grocery Stocks That Are Proving They Are Still Essential
• Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Taysha Gene Therapies Right Now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here